Hyper-IgE Syndrome: Treating the Skin Might Mean Touching the Immune Defect
A sixteen-year-old with STAT3 hyper-IgE syndrome has eczema bad enough to cost him his after-school job. The drug that could fix it targets the same cytokine pathway his underlying immune defect already disrupts — which is either irrelevant or exactly the point, depending on who's asked.
Caleb R. had been bagging groceries three afternoons a week since he turned sixteen, until his manager asked him to take time off after a customer complained about the cracked, weeping skin on his hands and forearms. His autosomal dominant STAT3 hyper-IgE syndrome was diagnosed at age four, after a pattern of retained primary teeth, recurrent staphylococcal skin abscesses, and pneumonia led to genetic testing that confirmed a pathogenic STAT3 variant. His eczema has never fully cleared since infancy, but the past year has been the worst of his life — open, excoriated plaques covering more than half his body surface, and two of his three most recent skin abscesses starting at sites of broken, eczematous skin rather than intact skin. He has also had two episodes of pneumonia requiring hospitalization in his life, both occurring before age ten, and none since, a pattern his immunologist reads as at least partly age-related maturation rather than pure prophylaxis effect.
His serum IgE, drawn this visit, is above 40,000 IU/mL, consistent with the disease's hallmark finding, and he remains on standing antistaphylococcal and antifungal prophylaxis that has kept his infection frequency roughly stable even as his skin disease has worsened. Dick et al., 2025, Pediatric Dermatology, described a growing case series of children with STAT3- and other genetically distinct hyper-IgE syndromes treated with dupilumab, with sustained falls in eczema body-surface involvement and no additional cutaneous or pulmonary infections on treatment. The children in it were young, though — the best-documented responder was eight — and Caleb is sixteen, with both his pneumonias behind him before age ten and none since. He is at a different point on the disease’s own arc than anyone the series actually followed, which cuts both ways: less to protect against than a young child, and less evidence describing him. What makes the decision genuinely contested rather than a simple extension of ordinary eczema care is that dupilumab blocks IL-4 and IL-13 signaling in a patient whose underlying genetic defect already disrupts a different but related arm of his immune system — and nobody yet has enough patients treated long enough to say with confidence what, if anything, adding a second immune-modulating mechanism does to his specific infection risk.
Which pathway a second drug would actually touch
His skin disease is now driving his infections, not just coexisting with them — two of his last three abscesses started at excoriated sites. Dick and colleagues published a growing case series in children with hyper-IgE syndrome treated with dupilumab, with substantial and durable drops in body-surface involvement and no new infections on treatment — in children younger than he is, which I’ll own as the weak point of citing it for him. I want to add dupilumab.
I hear the barrier-integrity argument, and it's a real one. What gives me pause is that his underlying STAT3 defect already impairs his Th17 response and his defense against staph and fungal infection specifically — adding a second immune-modulating drug on top of an already-abnormal immune system is not something I'd treat as risk-free just because the case series so far looks reassuring.
A handful of case reports without long-term infection surveillance data isn't the same evidence base we'd want before adding a new mechanism to a genetically immunodeficient patient's regimen.
It's worth being precise about which mechanisms are actually in tension here. Dupilumab blocks IL-4 receptor alpha, which sits on a different signaling pathway than the STAT3-dependent Th17 differentiation his genetic defect disrupts — they aren't the same axis, so the theoretical risk isn't that dupilumab compounds his existing infection vulnerability directly. That doesn't make it risk-free, but it does mean a monitored trial, with explicit infection surveillance built in from the start, is a reasonable way to test the real barrier-integrity benefit against a risk that current evidence hasn't actually shown, rather than declining based on a mechanism that doesn't fully apply.
Dupilumab was started with an explicit monitoring plan: skin surface area assessed monthly and infection frequency tracked prospectively rather than recalled retrospectively at his next scheduled visit. By month four his affected body surface area had fallen from over 50% to roughly 15%, with no new skin or pulmonary infections.
Not agreed: how long a clean infection record needs to run before the immunologist's caution is considered answered rather than merely unconfirmed — the dermatologist reads four infection-free months as reassuring, while the immunologist wants at least a year of prospective surveillance before treating the theoretical mechanism concern as settled.